Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics

Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to...

Full description

Bibliographic Details
Main Authors: Andisheh Abedini, Annette Plesner, Ping Cao, Zachary Ridgway, Jinghua Zhang, Ling-Hsien Tu, Chris T Middleton, Brian Chao, Daniel J Sartori, Fanling Meng, Hui Wang, Amy G Wong, Martin T Zanni, C Bruce Verchere, Daniel P Raleigh, Ann Marie Schmidt
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2016-05-01
Series:eLife
Subjects:
Online Access:https://elifesciences.org/articles/12977
id doaj-430cfdb339f14b1f94dfa0ddab3b017d
record_format Article
spelling doaj-430cfdb339f14b1f94dfa0ddab3b017d2021-05-05T00:24:29ZengeLife Sciences Publications LtdeLife2050-084X2016-05-01510.7554/eLife.12977Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeuticsAndisheh Abedini0Annette Plesner1Ping Cao2Zachary Ridgway3Jinghua Zhang4Ling-Hsien Tu5Chris T Middleton6Brian Chao7Daniel J Sartori8Fanling Meng9Hui Wang10Amy G Wong11Martin T Zanni12C Bruce Verchere13Daniel P Raleigh14Ann Marie Schmidt15https://orcid.org/0000-0001-8902-070XDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesChild and Family Research Institute, Department of Pathology and Laboratory Medicine and Department of Surgery, University of British Columbia, Vancouver, CanadaDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, University of Wisconsin-Madison, Madison, United StatesDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDepartment of Chemistry, University of Wisconsin-Madison, Madison, United StatesChild and Family Research Institute, Department of Pathology and Laboratory Medicine and Department of Surgery, University of British Columbia, Vancouver, CanadaDepartment of Chemistry, Stony Brook University, Stony Brook, United StatesDiabetes Research Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University School of Medicine, New York, United StatesIslet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to induction of rat INS-1 β-cell and murine islet toxicity. These globally flexible, low order oligomers upregulate pro-inflammatory markers and induce reactive oxygen species. They do not bind 1-anilnonaphthalene-8-sulphonic acid and lack extensive β-sheet structure. Aromatic interactions modulate, but are not required for toxicity. Not all IAPP oligomers are toxic; toxicity depends on their partially structured conformational states. Some anti-amyloid agents paradoxically prolong cytotoxicity by prolonging the lifetime of the toxic species. The data highlight the distinguishing properties of toxic IAPP oligomers and the common features that they share with toxic species reported for other amyloidogenic polypeptides, providing information for rational drug design to treat IAPP induced β-cell death.https://elifesciences.org/articles/12977amylinIAPPoligomerdiabetesamyloidislet amyloid polypeptide
collection DOAJ
language English
format Article
sources DOAJ
author Andisheh Abedini
Annette Plesner
Ping Cao
Zachary Ridgway
Jinghua Zhang
Ling-Hsien Tu
Chris T Middleton
Brian Chao
Daniel J Sartori
Fanling Meng
Hui Wang
Amy G Wong
Martin T Zanni
C Bruce Verchere
Daniel P Raleigh
Ann Marie Schmidt
spellingShingle Andisheh Abedini
Annette Plesner
Ping Cao
Zachary Ridgway
Jinghua Zhang
Ling-Hsien Tu
Chris T Middleton
Brian Chao
Daniel J Sartori
Fanling Meng
Hui Wang
Amy G Wong
Martin T Zanni
C Bruce Verchere
Daniel P Raleigh
Ann Marie Schmidt
Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics
eLife
amylin
IAPP
oligomer
diabetes
amyloid
islet amyloid polypeptide
author_facet Andisheh Abedini
Annette Plesner
Ping Cao
Zachary Ridgway
Jinghua Zhang
Ling-Hsien Tu
Chris T Middleton
Brian Chao
Daniel J Sartori
Fanling Meng
Hui Wang
Amy G Wong
Martin T Zanni
C Bruce Verchere
Daniel P Raleigh
Ann Marie Schmidt
author_sort Andisheh Abedini
title Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics
title_short Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics
title_full Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics
title_fullStr Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics
title_full_unstemmed Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics
title_sort time-resolved studies define the nature of toxic iapp intermediates, providing insight for anti-amyloidosis therapeutics
publisher eLife Sciences Publications Ltd
series eLife
issn 2050-084X
publishDate 2016-05-01
description Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to induction of rat INS-1 β-cell and murine islet toxicity. These globally flexible, low order oligomers upregulate pro-inflammatory markers and induce reactive oxygen species. They do not bind 1-anilnonaphthalene-8-sulphonic acid and lack extensive β-sheet structure. Aromatic interactions modulate, but are not required for toxicity. Not all IAPP oligomers are toxic; toxicity depends on their partially structured conformational states. Some anti-amyloid agents paradoxically prolong cytotoxicity by prolonging the lifetime of the toxic species. The data highlight the distinguishing properties of toxic IAPP oligomers and the common features that they share with toxic species reported for other amyloidogenic polypeptides, providing information for rational drug design to treat IAPP induced β-cell death.
topic amylin
IAPP
oligomer
diabetes
amyloid
islet amyloid polypeptide
url https://elifesciences.org/articles/12977
work_keys_str_mv AT andishehabedini timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT annetteplesner timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT pingcao timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT zacharyridgway timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT jinghuazhang timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT linghsientu timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT christmiddleton timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT brianchao timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT danieljsartori timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT fanlingmeng timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT huiwang timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT amygwong timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT martintzanni timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT cbruceverchere timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT danielpraleigh timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
AT annmarieschmidt timeresolvedstudiesdefinethenatureoftoxiciappintermediatesprovidinginsightforantiamyloidosistherapeutics
_version_ 1721476366477557760